GH Research PLC (NASDAQ:GHRS) Receives Average Recommendation of "Buy" from Brokerages

Shares of GH Research PLC (NASDAQ:GHRS - Get Free Report) have earned a consensus recommendation of "Buy" from the seven research firms that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $30.43.

A number of analysts recently commented on the company. Royal Bank of Canada assumed coverage on GH Research in a report on Friday, March 7th. They set an "outperform" rating and a $31.00 price target on the stock. Cantor Fitzgerald upgraded GH Research to a "strong-buy" rating in a research note on Tuesday, May 13th. HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of GH Research in a research note on Friday, May 9th. Guggenheim lowered their target price on GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, Wall Street Zen lowered GH Research from a "hold" rating to a "sell" rating in a research note on Thursday.

GH Research Stock Down 0.9%

GH Research stock traded down $0.10 during mid-day trading on Wednesday, reaching $11.17. 174,289 shares of the company's stock were exchanged, compared to its average volume of 181,107. The business's fifty day simple moving average is $10.34 and its 200 day simple moving average is $10.08. The firm has a market capitalization of $581.15 million, a PE ratio of -14.14 and a beta of 0.86. GH Research has a one year low of $6.00 and a one year high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.42. On average, sell-side analysts forecast that GH Research will post -0.8 earnings per share for the current year.

Institutional Trading of GH Research

Several hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in GH Research during the 4th quarter worth about $44,000. Palumbo Wealth Management LLC bought a new stake in shares of GH Research during the first quarter valued at about $142,000. XTX Topco Ltd purchased a new stake in shares of GH Research in the first quarter worth about $169,000. Two Sigma Investments LP bought a new position in shares of GH Research in the fourth quarter valued at approximately $117,000. Finally, Millennium Management LLC bought a new position in shares of GH Research in the fourth quarter valued at approximately $145,000. 56.90% of the stock is currently owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).